- Investopedia•7 hours ago
Roche Holdings AG RHHBY announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis. Roche’s share price ...
- Investor's Business Daily•8 hours ago
The FDA's approval of a multiple sclerosis drug from Roche is likely to be bittersweet for Biogen, analysts said Wednesday.
- Reuters•15 hours ago
Roche's multiple sclerosis (MS) drug Ocrevus won U.S. approval, putting the potential blockbuster back on track after a brief delay and giving a lift to patients with a form of the disease that until now had no approved treatment. The drug, also known as ocrelizumab and administered via infusion, becomes the first U.S. Food and Drug Administration-approved medicine for the primary progressive form of the neurological disease (PPMS). Ocrevus, to have a list price of $65,000 annually, undercutting rival Merck's Rebif by a quarter, is also approved to treat the most common form of MS, known as relapsing-remitting multiple sclerosis (RRMS).
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||268.27 x 100|
|Ask||268.51 x 300|
|Day's Range||268.20 - 273.91|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||15.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|